|
| Press Releases |
|
 |
|
| Wednesday, May 9, 2018 |
|
|
Helsinn Group announces the launch of the IV formulation of AKYNZEO(R) (fosnetupitant/palonosetron) in the United States |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the intravenous formulation of AKYNZEO(R) (a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) for injection has been launched in the United States by its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc.. more info >> |
|
| Friday, April 20, 2018 |
|
|
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of AKYNZEO(R) (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing CINV. more info >> |
|
| Tuesday, April 17, 2018 |
|
|
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy |
| Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma focused on oncology and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announce that they are collaborating on the development of an investigational highly-selective RET inhibitor TAS0286/HM05, being evaluated in non-small cell lung cancer and other carcinomas. more info >> |
|
| Wednesday, March 28, 2018 |
|
|
Helsinn Healthcare S.A.: Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced |
| Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announced that Lorenzo Pradella of GreenBone Ortho, srl and Gitte Pedersen of Genomic Expression, Inc. have been chosen as winners of the first ever Lyfebulb-Helsinn Innovation Awards in Oncology. more info >> |
|
| Friday, March 2, 2018 |
|
|
Helsinn Healthcare S.A.: Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology |
| Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announce the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. more info >> |
|
| Tuesday, October 17, 2017 |
|
|
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces the approval of Helsinn Pharmaceuticals (Beijing) Co. Ltd., Shanghai branch, on August 7, 2017 by the Shanghai Administration for Industry and Commerce with a 30-year term. The full address and contact details of the Shanghai branch are found at the end of this announcement. more info >> |
|
| Friday, September 9, 2016 |
|
|
Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss |
| Helsinn Therapeutics (U.S.) Inc., the pharmaceutical group focused on building quality cancer care, and patient network PatientsLikeMe have unveiled findings from an online survey that captured experiences and insights about unintended weight loss and its burden among 95 patients living with non-small cell lung cancer. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Genius Foundation's GENIUS Token Surges Following TGE, Briefly Tops $800 Million FDV
Apr 22, 2026 01:04: JST
|
|
|
Genius Foundation's GENIUS Token Surges Following TGE, Briefly Tops $800 Million FDV
Apr 21, 2026 22:46 HKT/SGT
|
|
|
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Apr 21, 2026 20:52 JST
|
|
|
Seven HKTDC Lifestyle and Licensing mega events to open next week
Apr 21, 2026 19:51: JST
|
|
|
New Report Reveals Widespread Misunderstanding of Consumer Messaging App Security Across Government and Critical Infrastructure
Apr 21, 2026 19:00 HKT/SGT
|
|
|
Seven HKTDC Lifestyle and Licensing mega events to open next week
Apr 21, 2026 18:51 HKT/SGT
|
|
|
Hitachi to establish a new company with Nojima under a strategic partnership to accelerate growth of its home appliance business
Apr 21, 2026 19:21 JST
|
|
|
Global Turbine Asia Advances Aerospace Growth, Capabilities and Talent Development Through Strategic Partnerships
Apr 21, 2026 17:39 HKT/SGT
|
|
|
GMG's Graphene Engine Oil Additive G(R) LUBRICANT: Patent Granted in USA; Allowed in China
Apr 21, 2026 17:07 HKT/SGT
|
|
|
トヨタ、幹部職人事について
Apr 21, 2026 16:00: JST
|
|
|
Demanlink Unveils Sarawak's First Telecommunications Smart Pole in Siburan and Debuts its First Built-to-Suit Tower in Bintulu
Apr 21, 2026 16:00 HKT/SGT
|
|
|
CNN、「Global Perspectives」イベントシリーズをバンコクで開催
Apr 21, 2026 12:50: JST
|
|
|
Australia's data centre leaders to meet amid surge in AI-driven infrastructure investment
Apr 21, 2026 12:41 HKT/SGT
|
|
|
百望股份最新白皮書聚焦BEPS 2.0落地與數字化監管變局 破解跨境出海稅務合規痛點
Apr 21, 2026 12:04 HKT/SGT
|
|
|
百望股份最新白皮书聚焦BEPS 2.0落地与数字化监管变局 破解跨境出海税务合规痛点
Apr 21, 2026 11:41 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
